SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
A Phase II Randomized Study.Primary objective:to investigate the 6-month progression-free
survival (PFS) rate i patients receiving SLOG or mFLFIRINOX as a first-line treatment for
locally advanced and metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital China Medical University Hospital,Taiwan E-DA Hospital Kaohsiung Chang Gung Memorial Hospital,Taiwan Kaohsiung Medical University Kaohsiung Medical University Hospital,Taiwan Linkou Chang Gung Memorial Hospital, Taiwan National Cheng Kung University Hospital,Taiwan National Cheng-Kung University Hospital National Taiwan University Hospital National Taiwan University Hospital, Taiwan Taipei Medical University Shuang Ho Hospital Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare,Taiwan Taipei Veterans General Hospital, Taiwan Tri-Service General Hospital